Polyomavirus JC (JCV) is the causative agent of a rare central nervous system demyelinating disease known as progressive multifocal leukoencephalopathy (PML). This fatal brain infection of immunocompromised persons occurred in ∼5% of AIDS patients before highly active antiretroviral therapies became available [1] . However, JCV infection is much more frequent: the virus infects 70%-90% of the adult population worldwide [2, 3] . After primary infection, which occurs during childhood without any known associated clinical manifestation, the virus persists lifelong in the kidneys. It is excreted in the urine of ∼40% of the general population 130 years old [4] [5] [6] [7] .
The JCV genome is a 5.1-kb supercoiled circular DNA divided into 3 main regions: the noncoding regulatory region, which contains the origin of replication; the early region, which encodes viral regulatory proteins large T and small t; and the late region, which encodes the structural proteins VP1, VP2, VP3, and agnoprotein. The JCV noncoding regulatory region supports an extensive strain-to-strain variability. The sequences identified in PML-affected brains show a rearranged pattern by deletions or duplications derived from the "archetypal" form found in urinary tract virus [8] [9] [10] . In contrast, the coding regions are highly conserved. Polymerase chain reaction (PCR) and direct sequence analysis of the gene coding for the major capsid protein VP1 allow the distinction of у7 genotypes of JCV [5, [11] [12] [13] . The JCV genotypes evolved in specific geographic regions. JCV type 1 predominates in Europe and the United States, whereas type 2, which is found in Asia, is divided into 2 main subtypes-2a in northeastern Asia, including China and Japan, and 2b in western Asia. JCV types 3 and 6 are African genotypes, found in Tanzania and in Ghana, respectively [14, 15] . Type 4, which presently is found only in the United States, seems to be a recombinant of the major part of the type 1 genome and a short segment of the type 3 VP1 gene [5, 16] . JCV type 5 was shown to be a recombinant between type 2b and type 6 [17] . Type 7, which is closely related to type 2 [12] , is the dominant strain in southern China and Southeast Asia.
Because JCV type 1 is most prevalent in other European countries, the first aim of this study was to determine which genotypes could be found in France. We therefore examined the genotype profile of JCV strains in 65 JCV-positive urine samples from 5 different French cities.
Previous studies in the United States suggested that JCV type 2, especially type 2b, was more likely to cause PML [16, 18] . A different genotype distribution in France could prove helpful to confirm this biologic behavior difference between genotypes. Thus, we investigated the hypothesis of type-specific neuropathogenicity by determining the JCV genotypes in cerebral samples of 56 patients with PML and by comparing them with the urinary genotype distribution in 65 patients without PML.
Materials and Methods
Urine samples. Urine samples were collected in infectious diseases or internal medicine departments in hospitals in Bordeaux (southwestern France), Toulouse (south), Rennes (west), Rouen (north), and Paris. In total, 65 JCV-positive urine samples, taken from 54 immunocompromised patients with no sign of PML and from 11 immunocompetent persons, were included in this study. All samples were sent to the laboratories for diagnostic purposes. Among the immunocompromised patients, 43 were infected with human immunodeficiency virus (HIV), and 11 were organ or tissue graft recipients (bone marrow or kidney). Thirty-three patients came from Bordeaux, 13 from Rennes, 15 from Toulouse, 3 from Paris, and 1 from Rouen. The mean age of the patients was 41.6 years (range, 21-74 years; median, 39 years). Thirteen were women, and 52 were men. Ethnic origins were as follows: European, 93.8% (61); North African, 4.6% (3); and Asian, 1.5% (1) .
Fresh urine samples (40-100 mL) were stored at 4ЊC until DNA extraction, with no previous treatment. Two different techniques, varying by the centers, were used for DNA extraction. In Bordeaux and Rouen, 200 mL of urine was digested overnight with proteinase K (25 mg/mL) at 56ЊC in a total volume of 500 mL, and DNA was extracted with a classic phenol-chloroform and chloroform-isoamyl alcohol procedure. The pellet was resuspended in 50 mL of TE (10 mM Tris and 1 mM EDTA, pH 8). In Rennes, Toulouse, and Paris, 100 mL of urine was extracted by use of the QIAamp Blood Mini Kit (Qiagen) or High Pure (Roche Diagnostics), according to the recommendations of the manufacturers.
PML samples. Fifty-six JCV-positive cerebral samples (22 cerebrospinal fluid and 34 brain biopsy samples) were obtained from 53 HIV-infected patients with PML and 3 patients with PML who presented with other underlying immunodeficiencies (renal transplantation, autoimmune disease, or chronic lymphocytic leukemia). Forty of these patients were analyzed in Reims hospital (northeast), which represented the reference center for PML virologic diagnosis in France. Ten were treated in Bordeaux, 4 in Paris, and 2 in Toulouse. The mean age of the patients with PML was 39.9 years (range, 24-70 years; median, 37.5 years). There were 11 women and 45 men. Their ethnic origin was comparable to that of the patients without PML: European, 92.8% (52); African, 5.4% (3); and Asian, 1.8% (1).
DNA was extracted from brain biopsy samples by the technique described by Moret et al. [19] . In brief, brain samples were digested overnight with proteinase K and SDS at 37ЊC, and DNA was extracted with phenol-chloroform and chloroform-isoamyl alcohol before precipitation with ethanol and sodium acetate. The QIAamp Blood Mini Kit (Qiagen) was used for DNA extraction from cerebrospinal fluid.
Amplification of VP1 gene fragment. A seminested PCR was used for the amplification of 494 bp within the VP1 gene. The first PCR round was done with the primer pair M5 (5 -GTTTGTAAA-CATGCCACAGACATC-3 ) and P13 (5 -TTCCACTACCCA-ATCTAAATGAGG-3 ) [20] , and the second was done with the primers M5 and JLP1 (5 -CTCATGTGGGAGGCTGT[G/T-]ACCT-3 ) [5] . Both PCR rounds were conducted on a Perkin Elmer Cetus 9600 sequencer.
Cycle sequencing. PCR products were purified by use of the agarose gel QIAEX kit (Qiagen) or S400 spin columns (Amersham Pharmacia Biotech), according to the procedure described by the manufacturers. Both strands of the purified PCR products were used as templates in a single-cycle reaction, by use of the dideoxy chain-termination method with the dRhodamine Dye Terminators kit (PE Biosystems) and the JLP1 and M5 primers, in 2 separate reaction mixtures. Sequence reaction products were precipitated to remove excess dideoxynucleotides.
After electrophoresis on a 6% polyacrylamide gel containing 6 M urea and 1ϫ Tris borate-EDTA, the sequences were analyzed with an ABI 377 automatic sequencer (PE Biosystems) with Sequencing Analysis 3.3 software (Applied Biosystems). The sequences were compared with references and with each other by use of Sequence Navigator software (Applied Biosystems).
The 494-bp amplified fragment of the VP1 gene contained 17 typing sites that differentiated the major JCV types and subtypes [5, [21] [22] [23] [24] [25] [26] [27] . However, it failed to distinguish between types 5 and 6.
Reference sequences. The sequences referred to were provided by GenBank and the European Molecular Biology Laboratory data library: complete genome JCV (Mad-1; accession no. J02227) [21] ; VP1 sequence of type 1b (AF015527) [22] , type 2a strain Tokyo-1 (AF030085) [23] , type 2b strain GS/B (M20322) [24] , type 2c (AF015534) [23] , type 2d (AF015536) [23] , type 3 (U73500) [25] , type 4 (AF015528) [5] , type 5 (AF015684) [23] , type 6 (AF015537) [26] , and type 7 strain Tai-3 (U61771) [27] . Numbering of the coding region is based on the JCV (Mad-1) sequence.
Statistical methods. JCV type distribution in brain and urine samples was analyzed in a or contingency table by use 2 ϫ 2 2ϫ 4 of the x 2 statistic with Yates's correction for continuity. All variable analyses were done by use of Epi-Info (Centers for Disease Control and Prevention, version 6). 
Results

JCV genotype distribution in urine.
NOTE. Seventeen type-specific nucleotide positions are indicated in italics. Sequence of 1c, a potential new subtype, is also indicated. There was no correlation between JCV type distribution in urine and the geographic location of the patients, for the 3 hospitals which contributed mostly to this part of the study.
The strains analyzed in 11 immunocompetent persons came from a single city. Comparison of these results with those obtained for 22 immunocompromised patients living in the same area showed no significant difference in genotype distribution (table 3) .
The only 3 type 3 isolates were found in the 3 North African patients (Algeria and Morocco). The single Asian patient carried a type 2b JCV strain. However, 7 additional type 2 viruses were detected in European patients.
JCV genotype distribution in cerebral samples. As in urine, all 4 major JCV genotypes were found in the brains of patients with PML ( However, infection with genotype 1 or 2 was associated with a significant risk of developing PML, compared with other genotypes (OR, 3.29; 95% CI, 1.23-9).
Discussion
JCV genotyping was never attempted in France before, although several studies provided data for other European countries. We took advantage of the existence of an Agence Nationale de Recherche sur le SIDA French Group for the Study of Polyomaviruses [28] to organize a nationwide study. Special attention was given to HIV-infected patients, because PML represents a dramatic opportunistic disease risk for them. This potential patient selection bias could have affected the interpretation of results. However, the comparison of JCV genotype distribution among HIV-infected and immunocompetent persons, attempted in a single city, indicated no difference.
The 5 participating laboratories first elaborated common virologic procedures. Only extraction methods differed because of specific hospital facilities. The possibility of PCR contamination was carefully examined because a seminested amplification was chosen.
A seminested PCR impairs the identification of minor sequences, therefore underestimating the existence of double virus populations. These have been described elsewhere by others [5, 16, 29] and also occasionally observed in French patients with, for example, 2 different JCV genotypes in the urine and peripheral blood leukocytes (V.D., unpublished data). Indeed, we did not encounter any double viral infection among the 121 samples.
This study led to the description of a potential new JCV subtype within genotype 1. Subtype 1c, characterized by nucleotide mutations at positions 1940 and 2011, was identified in 2 patients living 800 km apart, once in urine and once in the brain. Its presence in additional patients is therefore likely. However, we were not able yet to ascertain the identification of this subtype by sequencing the entire viral genome.
JCV genotypic distribution in the urine of French patients may be compared with previous results obtained in other countries. Type 1 clearly dominated, as in the studies performed in the United States [5] , but all genotypes were encountered. Subtype 1b represented two-thirds and subtype 1a represented onethird of type 1 infections. In Hungary, type 1 was described almost exclusively [30] . This may be linked with the selection of patients (i.e., those with multiple sclerosis); on the other hand, it could reflect the ethnic specificity of the Hungarian community. Our results were also in agreement with those obtained in Spain, Italy, the United Kingdom, and Sweden [13] , although genotypes 1 and 4 could not be technically distinguished in the latter study. Indeed, genotype 4 reached the striking prevalence of 30.8% among French patients, whereas its presence was noted in only 16% of Americans [5] . These 20 persons were of European origin. Because genotype 4 results from the recombination of "African" genotype 3 and "European" genotype 1, it is possible that it first occurred in Europe before being carried over to the New World.
All JCV genotypes were found in the central nervous system of patients with PML but not in the same proportions as in the peripheral compartment. Genotype 1 dominance was even more marked than in a previous study (46%) [16] , constituting two-thirds of the viral strains. Type 2 viruses came second, with only 20%, instead of the 48% encountered in American patients. Furthermore, infection with genotypes 1 or 2 was correlated with a higher risk of developing PML, but neither infection with genotype 1 nor infection with genotype 2 alone was associated with a significant risk. Therefore, our observations indicated a link between genotype and neuropathogenicity, but they did not strictly support the genotype 2 hypothesis.
It was suggested that the rarity of genotype 2 viruses in West Africa was responsible for the lack of PML among AIDS patients in this region [31] . Such comments may be questionable, because patients in these regions of the world may die long before the onset of PML. The prevalence of PML in Asian developing countries would be interesting to analyze, because genotype 2 may represent most viral species among these patients.
On the other hand, the relative underrepresentation of type 4 JCV in the brain (3-fold less than in the periphery) was rather evocative. The possible limited pathogenicity of genotype 4 was suggested by Agostini et al. [18] , but results did not reach significance. Although these data need to be confirmed, the presence of type 4 JCV in urine could represent a favorable factor for immunocompromised patients at risk of developing PML.
This potential link between neuropathogenicity and genotypes could be considered as artifactual, because most control subjects in this study (Bordeaux) did not live in the same geographic area as did the patients with PML (Reims). However, Reims Hospital was for more than a decade the reference center for PML diagnosis in France and therefore tested samples from all French regions.
Although the connection between genotype and neuropathogenicity represents a controversial issue, its mechanism deserves further investigations. In addition to its structural function, VP1 plays other important roles in the polyomavirus life cycle. This protein possesses the receptor-binding domain, which makes it crucial in virus attachment and, consequently, in defining viral tropism and pathogenesis. As an example, a single-amino acid substitution in murine polyomavirus VP1 determines the plaque size and hemagglutination behavior of polyomavirus [32] . Subsequently, it has been shown that the presence of amino acid residue 92 at this position interferes with the binding of branched a(2-6)-linked sialic acid chains, which serve as specific cell receptors for polyomavirus [33] . Infection of glial cells by human JCV is also mediated by an N-linked glycoprotein containing terminal a(2-6)-linked sialic acids [34] . This initial interaction could be affected by amino acid variations of VP1 linked to the different genotypes and could modify the neuropathogenicity of those JCVs.
The need for multicenter studies, organized within a medical and scientific network such as ours, deserves to be underlined. However, because of the present efficacy of antiretroviral regimens, the potential link between neuropathogenicity and JCV genotypes, although it represents an interesting pathophysiologic question, may not be determined easily in the future because of the limited number of patients now developing PML.
